An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts

Yukinari Kato, Tomokazu Ohishi, Junko Takei, Takuro Nakamura, Masato Sano, Teizo Asano, Yusuke Sayama, Hideki Hosono, Manabu Kawada, Mika K. Kaneko

研究成果: Article査読

5 被引用数 (Scopus)

抄録

Trastuzumab is a humanized antibody against human epidermal growth factor receptor 2 (HER2) that offers significant survival benefits to patients with HER2-overexpressing breast or gastric cancer. HER2 is also known to be overexpressed in colon cancers. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, κ) was characterized for its anticancer activity in colon cancers. H2Mab-19 showed both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against Caco-2, a colon cancer cell line. Furthermore, H2Mab-19 significantly reduced tumor development in a Caco-2 xenograft model. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing colon cancers.

本文言語English
ページ(範囲)123-128
ページ数6
ジャーナルMonoclonal antibodies in immunodiagnosis and immunotherapy
39
4
DOI
出版ステータスPublished - 2020 8月 1

ASJC Scopus subject areas

  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル